http://orcid.org/0000-0001-5343-701X
References
- Asha S, Vidyavathi M. (2010). Role of human liver microsomes in in vitro metabolism of drugs–a review. Appl Biochem Biotechnol 160:1699–722.
- Bernard S, Neville KA, Nguyen AT, Flockhart DA. (2006). Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications. Oncologist 11:126–35.
- Beverage JN, Sissung TM, Sion AM, et al. (2007). CYP2D6 polymorphisms and the impact on tamoxifen therapy. J Pharm Sci 96:2224–31.
- Cadoudal T, Distel E, Durant S, et al. (2008). Pyruvate dehydrogenase kinase 4: regulation by thiazolidinediones and implication in glyceroneogenesis in adipose tissue. Diabetes 57:2272–9.
- Gowda R, Inamdar GS, Kuzu O, et al. (2017). Identifying the structure-activity relationship of leelamine necessary for inhibiting intracellular cholesterol transport. Oncotarget 8:28260–77.
- Gowda R, Madhunapantula SV, Kuzu OF, et al. (2014a). Targeting multiple key signaling pathways in melanoma using leelamine. Mol Cancer Ther 13:1679–89.
- Gowda R, Madhunapantula SV, Sharma A, et al. (2014b). Nanolipolee-007, a novel nanoparticle-based drug containing leelamine for the treatment of melanoma. Mol Cancer Ther 13:2328–40.
- Ingelman-Sundberg M. (2005). Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 5:6–13.
- Jeoung NH, Harris RA. (2010). Role of pyruvate dehydrogenase kinase 4 in regulation of blood glucose levels. Korean Diabetes J 34:274–83.
- Kovaleva KS, Yarovaya OI, Shernyukov AV, et al. (2017). Synthesis of new heterocyclic dehydroabietylamine derivatives and their biological activity. Chem Heterocycl Compd (NY) 53:364–70.
- Kuzu OF, Gowda R, Sharma A, Robertson GP. (2014). Leelamine mediates cancer cell death through inhibition of intracellular cholesterol transport. Mol Cancer Ther 13:1690–703.
- Lee J, Liu X. (2007). The conduct of drug metabolism studies considered good practice (II): in vitro experiments. Curr Drug Metab 8:822–9.
- Lee SK, Kim DH, Yoo HH. (2011). Comparative metabolism of sildenafil in liver microsomes of different species by using LC/MS-based multivariate analysis. J Chromatogr B Analyt Technol Biomed Life Sci 879:3005–11.
- Lin JH, Lu AYH. (1997). Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev 49:403–49:
- Prasad B, Garg A, Takwani H, Singh S. (2011). Metabolite identification by liquid chromatography-mass spectrometry. Trends Analyt Chem 30:360–87.
- Sehrawat A, Kim SH, Hahm ER, et al. (2017). Cancer-selective death of human breast cancer cells by leelamine is mediated by bax and bak activation. Mol Carcinog 56:337–48.
- Sim J, Nam W, Lee D, et al. (2015). Selective induction of hepatic cytochrome P450 2B activity by leelamine in vivo, as a potent novel inducer. Arch Pharm Res 38:725–33.
- Song M, Lee D, Lee T, Lee S. (2013). Determination of leelamine in mouse plasma by LC-MS/MS and its pharmacokinetics. J Chromatogr B Analyt Technol Biomed Life Sci 931:170–3.
- Tiller PR, Romanyshyn LA. (2002). Liquid chromatographic/tandem mass spectrometric quantification with metabolite screening as a strategy to enhance the early drug discovery process. Rapid Commun Mass Spectrom 16:1225–31.
- Zanger UM, Schwab M. (2013). Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138:103–41.